Drug intelligence / Profile preview

[pt(bipy)(ibgly)]no3

Development stage: Preclinical
Modality: Small Molecules

Overview

[Pt(bipy)(IBgly)]NO3 is a platinum(II) coordination complex that has been studied as a potential anticancer agent. The complex is composed of a platinum(II) ion coordinated by one 2,2'-bipyridine (bipy) ligand, one N-isobutylglycine (IBgly) ligand, and a nitrate counterion. Its mechanism of action involves binding to DNA, primarily through electrostatic and groove binding interactions, rather than intercalation, as demonstrated by spectroscopic and computational studies[1]. The compound exhibits cytotoxic activity against human colon cancer cells in vitro, with IC50 values of 47.30 μM after 72 hours, and shows greater inhibitory effects compared to carboplatin, a clinical platinum-based chemotherapeutic[1].

Other names: [Pt(bipy)(IBgly)]NO3

Targets

DNA

Beyond the preview

Go deeper on [pt(bipy)(ibgly)]no3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [pt(bipy)(ibgly)]no3.

Explore the full profile